Search
Now showing items 1-5 of 5
SOD2, a Potential Transcriptional Target Underpinning CD44-Promoted Breast Cancer Progression
(
MDPI
, 2022 , Article Review)
CD44, a cell-adhesion molecule has a dual role in tumor growth and progression; it acts as a tumor suppressor as well as a tumor promoter. In our previous work, we developed a tetracycline-off regulated expression of CD44’s ...
Comment on the manuscript “Histological subtype is associated with PD-L1 expression and CD8+ T-cell infiltrates in triple-negative breast carcinoma” by Salisbury et al. (Ann Diagn Pathol 2022; 57: 151901, https://doi.org/10.1016/j.anndiagpath.2022.151901)
(
Elsevier
, 2022 , Other)
I read with great interest a recent paper written by Salisbury et al. published in the April 2022 issue of the Annals of Diagnostic Pathology [1]. In their study, the authors explored a small cohort of triple-negative ...
HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome.
(
Springer
, 2022 , Other)
Apocrine carcinoma of the breast (APO) expresses HER2 in 30-50% of cases. This study explored the clinicopathological features and outcome of HER2+/APO and matched HER2+/NST cohort. We used the SEER database to explore the ...
Acinic cell carcinoma of the breast: A comprehensive review
(
Elsevier
, 2022 , Article)
Acinic cell carcinoma of the breast is a rare special subtype of breast cancer in the category of salivary gland-type tumors. It is morphologically similar to acinic cell carcinomas of salivary glands and pancreas and has ...
Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers
(
Association of Basic Medical Sciences of FBIH
, 2022 , Article)
Antibody-drug conjugates represent a new class of highly potent antineoplastic drugs built by attaching a small molecule of an anticancer drug (payload) or another therapeutic agent to an antibody recognizing an epitope ...